Get the Stockscreener App
0.79
0.95%
0.0074
Pre-market:
.77
-0.02
-2.53%
Longeveron Inc stock is traded at $0.79, with a volume of 162.64K.
It is up +0.95% in the last 24 hours and up +17.82% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$0.7826
Open:
$0.82
24h Volume:
162.64K
Relative Volume:
0.12
Market Cap:
$24.96M
Revenue:
$1.22M
Net Income/Loss:
$-22.43M
P/E Ratio:
-0.6832
EPS:
-1.1564
Net Cash Flow:
$-18.78M
1W Performance:
+4.77%
1M Performance:
+17.82%
6M Performance:
+43.56%
1Y Performance:
-39.23%
1-Day Range:
$0.78
$0.82
1-Week Range:
$0.7408
$0.82
52-Week Range:
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.79 | 24.96M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
Stem cell firm Longeveron seeks Alzheimer’s, heart partners at BIO 2026 - Stock Titan
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesShare Repurchase Impact - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron Inc. (LGVN) Extends Decline: Tests Key Support at $0.74 After 4.9% DropDebt Free Companies - newsline.com
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock RallyAdjusted Earnings Analysis - newsline.com
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data - Investing.com India
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron Inc. (LGVN) Edges Higher Amid Stabilization at $0.72Dividend Growth Stocks - The Legal Advocate
[ARS] Longeveron Inc. SEC Filing - Stock Titan
Longeveron (NASDAQ: LGVN) plans reverse split, bigger share pool and incentive plan - Stock Titan
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering ... - Caledonian Record
Longeveron Issues Letter to Stockholders Highlighting - GlobeNewswire
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model - MSN
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift By Investing.com - Investing.com Nigeria
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift - Investing.com
[SCHEDULE 13G] Longeveron Inc. Passive Investment Disclosure (>5%) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Earnings Call: Trial Milestones Amid FDA Hurdles - TipRanks
Longeveron Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):